I just want to clarify that the two million doses per month that has been referenced by the honourable member and in the previous question relates to the Biologics Manufacturing Centre, which is now under way. Construction is going well. It will be completed by the end of July. Then we will begin a technology transfer process to position us to have engineering runs in production by the end of this calendar year. That is the facility on which we're working with Novavax under an MOU to pursue production at that facility.
Again, I think the distinction to be made here is that with that scale of production with the capability of our scientists at the Human Health Therapeutics Research Centre, Novavax was willing to embark because that was going to serve its commercial purposes, and, obviously, support making Canadian vaccine and its product in this country.
The question of the pilot plant is very different, and I think that's where there's a limitation in terms of what any large global manufacturer would do at that level of production with Canada. I think that opportunity has not presented itself, and I think there's good reason to explain why not, but, again, we're pleased that the large-scale Biologics Manufacturing Centre has made some progress with the recent MOU.